In April, we anticipated a pullback for JNJ, and since then, the stock has dropped approximately 7%, aligning with our expectations. The current trend suggests further downward movement, reinforcing our previous analysis.
We are focusing on the support zone ranging from $134 to $116, with a potential lower bound at $109, the Corona-Low. The ongoing pullback could...
If you haven`t bought JNJ before the previous earnings:
Then analyzing the options chain and the chart patterns of JNJ Johnson & Johnson prior to the earnings report this week,
I would consider purchasing the 145usd strike price Puts with
an expiration date of 2025-1-17,
for a premium of approximately $7.55.
If these options prove to be profitable prior to the...
Johnson & Johnson (NYSE: NYSE:JNJ ) has kicked off 2024 with a resounding victory, showcasing robust first-quarter earnings that outpaced Wall Street estimates and signaling a promising trajectory for the rest of the year.
The pharmaceutical giant reported an impressive adjusted EPS of $2.71, marking a remarkable 12.4% surge compared to the previous year. This...
Rallybio Corporation (Nasdaq: NASDAQ:RLYB ) is hitting the accelerator pedal after announcing a groundbreaking collaboration with Johnson & Johnson to combat fetal and neonatal alloimmune thrombocytopenia (FNAIT).
In a strategic move aimed at advancing therapeutic solutions for pregnant individuals at risk of FNAIT, Rallybio revealed plans for RLYB212, a...
Hello,
Welcome to this analysis about the stock JOHNSON&JOHNSON, looking at the 4-hour timeframe perspectives. In my analysis recently I detected an interesting formational structure with J&J which has the ability to show up a determined breakout. As the corona pandemic moved on there emerged several pharmacy companies wanted to invent the covid-19 vaccines,...
Hello, Traders Investors And Community, welcome to this analysis about the recent events, the current price-structure and what we can expect the next hours and days within J&JOHNSON. As I already mentioned in previous analysis in the current corona-crisis there are gainers and losers who are profiting either out of the crisis or having deficiencies to catch up...
Hello, according to Johnson & Johnson stock analysis. There is a good opportunity to buy or invest in stocks for the long term. Especially since the arrow came out of the rectangle. It also broke the resistance at 166. An ascending channel started to form, which indicates that the stock is very positive. Good luck everyone
Retest support when last breakout after earning
Good risk and reward
Good entry point to a company that can keep forever
If trading:
SL at pink line
TP 2/3 at blue line and let 1/3 run. Change SL to entry price once hit the blue line tp
It is plausible to consider that Johnson & Johnson's decision to spin off Kenvue might be linked to an effort to mitigate potential legal liabilities stemming from its talc-based products, which have been implicated in cases of cancer in the US and Canada. This strategic maneuver could potentially offer a layer of legal protection. Shareholders are expected to...
Analyzing the options chain of JNJ Johnson & Johnson prior to the earnings report this week,
I would consider purchasing the 160usd strike price Calls with
an expiration date of 2023-9-15,
for a premium of approximately $3.85.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
Looking forward to read your...
Analyzing the options chain of JNJ Johnson & Johnson prior to the earnings report this week, I would consider purchasing
at the money Calls with a 165usd strike price and an expiration date of 2023-4-21, for a premium of approximately $2.36.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
I am interested...
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral...
Hi,
The market has made some pretty good moves up and the current slight correction is bringing prices back to technically good levels and Johnson & Johnson is one of them.
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer goods.
Technically, it has been quite difficult...
Both macro (lawsuit, bankrupcy denied to mitigate fines) and technical points to downside in the short term. Here we see a head and soulders formation, with downside target coinciding with monthly 100 SME. Strong support for long term hold.
Inv H&S in the making
Price should come down first to test the level of support (RS) then shoot up to $176.00.
RSI also should drop a bit before breaking the downtrend.
Concerns:
Price is <200MA and the 21>7 - Bearish...
Bias - Neutral with hopeful bullish setup later on
Where are we going with this one? Very likely further down on the largest pharmaceutical firm in the world. As you can see confirmation has been crossed, signifying a start of a new zigzag.
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with...
JNJ feeling weak right now while moving within two descending channels. Currently the price is at the top of the minor channel, which should increase the selling pressure very soon.
